
ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study
This study assessed whether PreciseBreast and/or AI-Grade models are prognostic for Distant Recurrence-Free Interval (DRFI), predictive ofchemotherapy benefit, & to confirm how AI-Grade redefines IBC biologic phenotype beyond traditional histologic grading in HR+, node-negative (N0) patients (pts) from NSABP B-20.
.jpg)